Day One Biopharmaceuticals Inc (NASDAQ: DAWN) is -3.70% lower on its value in year-to-date trading and has touched a low of $9.67 and a high of $17.85 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The DAWN stock was last observed hovering at around $14.41 in the last trading session, with the day’s loss setting it -0.35%.
Currently trading at $14.06, the stock is -5.78% and -8.04% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.72 million and changing -2.43% at the moment leaves the stock 4.99% off its SMA200. DAWN registered 10.27% gain for a year compared to 6-month gain of 19.15%. The firm has a 200-day simple moving average (SMA200) of -$4.19.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -4.55% loss in the last 1 month and extending the period to 3 months gives it a 0.43%, and is -0.99% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.89% over the week and 5.41% over the month.
Day One Biopharmaceuticals Inc (DAWN) has around 155 employees, a market worth around $1.23B and $0.00M in sales. Distance from 52-week low is 45.40% and -21.23% from its 52-week high. The company has generated returns on investments over the last 12 months (-54.52%).
Day One Biopharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$0.66.The EPS is expected to shrink by -8.14% this year
213 institutions hold shares in Day One Biopharmaceuticals Inc (DAWN), with institutional investors hold 111.04% of the company’s shares. The shares outstanding are 87.23M, and float is at 58.94M with Short Float at 15.24%. Institutions hold 89.17% of the Float.
The top institutional shareholder in the company is RA Capital Management, L.P. with over 7.81 million shares valued at $93.25 million. The investor’s holdings represent 8.98% of the DAWN Shares outstanding. As of Jun 29, 2023, the second largest holder is Atlas Venture Life Science Advisors, LLC with 7.61 million shares valued at $90.84 million to account for 8.75% of the shares outstanding. The other top investors are FMR, LLC which holds 7.56 million shares representing 8.69% and valued at over $90.27 million, while Vanguard Group Inc holds 4.93% of the shares totaling 4.28 million with a market value of $51.15 million.
Day One Biopharmaceuticals Inc (DAWN) Insider Activity
The most recent transaction is an insider sale by Blackman Samuel C., the company’s HEAD OF R&D. SEC filings show that Blackman Samuel C. sold 10,000 shares of the company’s common stock on Mar 25 ’24 at a price of $16.01 per share for a total of $0.16 million. Following the sale, the insider now owns 1.18 million shares.
Day One Biopharmaceuticals Inc disclosed in a document filed with the SEC on Mar 11 ’24 that Blackman Samuel C. (HEAD OF R&D) sold a total of 30,000 shares of the company’s common stock. The trade occurred on Mar 11 ’24 and was made at $15.24 per share for $0.46 million. Following the transaction, the insider now directly holds 1.19 million shares of the DAWN stock.
Still, SEC filings show that on Feb 27 ’24, Blackman Samuel C. (HEAD OF R&D) disposed off 20,000 shares at an average price of $16.11 for $0.32 million. The insider now directly holds 1,224,662 shares of Day One Biopharmaceuticals Inc (DAWN).
